SILO (Silo Pharma, Inc.) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Silo Pharma, Inc. (SILO) delegates its entire production cycle and testing to external contractors, relying fully on third-party vendors. This chart of EV/EBITDA metrics is fixed at 0.00, while management develops microdosing for the treatment of inflammation and neurology. The business relies on venture capital and clinical trials against Alzheimer's, ignoring general market trends.

SILO (Silo Pharma Inc.) Company Value to EBITDA history from 11/23/2025 to 11/13/2026

Comprehensive metric breakdowns and analytics for Silo Pharma Inc. (SILO)

- market price and analyst price targets:

Price Chart Silo Pharma|SILO - Forecast Levels Chart

- business market valuation indicators:

Market Value Silo Pharma, Inc.|SILO - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share Silo Pharma|SILO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio silopharma.com|SILO - Cumulative Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

SILO - Company Net Income|Expected Profit Silo Pharma, Inc.|SILO - Market Cap to Earnings|Projected Price to Earnings Silo Pharma|SILO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Silo Pharma, Inc.|SILO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Silo Pharma|SILO - Earnings per share for the trailing year|Quarterly EPS earnings growth silopharma.com|SILO - Earnings growth in current year|Net earnings per share growth forecast for next year Silo Pharma, Inc.

- revenue and sales details:

SILO - Company Sales Revenue|Company Projected Revenue Silo Pharma, Inc.|SILO - Market Cap to Revenue|Forward P/S Multiple Silo Pharma, Inc.

Initial company analysis:SILO (Silo Pharma)

Identifying assets with high fundamental resilience requires analyzing the total enterprise value relative to its operating profit before taxes, depreciation, and amortization. This metric compares market capitalization, adjusted for net debt, against actual cash flow to identify company undervaluation. For Silo Pharma, Inc. (SILO), which optimizes R&D through university outsourcing, the EV/EBITDA valuation multiple reflects the efficiency of this capital expenditure reduction model.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|MNMD (MindMed) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bright Minds Corp (DRUG)|EV/EBITDA Multiple VNDA|CYBN (cybin.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Company Value to EBITDA|CING - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio China Pharma Holdings CPHI|CMND: EV/EBITDA Multiple|PBM - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SciSparc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SEEL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virpax Pharmaceuticals (VRPX)|KRTX - Company Value to EBITDA